Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Drug Profile

Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Alternative Names: CDX-085; Heptax; XanCor

Latest Information Update: 15 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardax Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Xanthophylls
  • Mechanism of Action Antioxidants; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypertriglyceridaemia; Liver disorders; Metabolic syndrome; Osteoarthritis; Thrombosis
  • Research Atherosclerosis; Cognition disorders; Type 2 diabetes mellitus
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 15 Jun 2018 Astaxanthin is still in preclinical trials for Hypertriglyceridaemia, Liver disorders, Thrombosis(Prevention), Metabolic syndrome in USA (Cardaxpharma pipeline June 2018)
  • 15 Jun 2018 Preclinical trials in Osteoarthritis in USA (PO) (Cardax pharma pipeline May 2018)
  • 13 Jun 2018 Cardax plans to submit an orphan drug designation application for a anti-inflammatory drug candidate to the FDA within twelve months
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top